drugset
drugset / Trial / NCT04696952

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

NCT04696952 ↗

Phase 1 Completed 61 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

A clinical study to evaluate the residual effects of TS-142 on driving performance in healthy and elderly subjects.

Timeline

Start
2021-01-16
Primary completion
2022-01-05
Completion
2022-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-142 Small molecule 10 mg —
Subject TS-142 Small molecule 20 mg —
Subject Zopiclone Small molecule 7.5 mg —

Indications

No indication recorded.